search
Back to results

Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study (GREEN)

Primary Purpose

Stroke, Acute, Stroke, Ischemic

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Glenzocimab
Placebo
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute focused on measuring Platelet glycoprotein VI, Endovascular therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or older (Age≥18 years)
  2. No significant pre-stroke disability (pre-stroke mRS must be equal to 0 or 1);
  3. Indication of EVT within the time-window of 0 to 24 hrs in participants treated with or without intravenous thrombolysis;
  4. Participants presenting with a target mismatch defined by an initial infarct volume (ischemic core) of less than 70 ml, a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more, and an absolute volume of potentially reversible ischemia (penumbra) of 15 ml or more on magnetic resonance imaging (MRI) or, when this is not possible, on perfusion computed tomography (CTP);
  5. Occlusion of the cervical or intracranial internal carotid artery (ICA) or the proximal middle cerebral artery (MCA - M1 and M2), on magnetic resonance angiography (MRA) or, when this is not possible, on CT angiography (CTA);
  6. Informed consent signed:

    • By the patient
    • Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent by written as per L. 1111-6,
    • In a situation urgently and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow him to consent.
  7. Post-menopausal women defined as not having menses for 12 months without an alternative medical cause. For WOCBP, a highly effective birth control method should be in place that can achieve a failure rate of less than 1% per year that should last for at least 2 months after IMP administration.

    Birth control methods which may be considered as highly effective in WOCBP include:

    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (intravaginal, transdermal),
    • progestogen-only hormonal contraception associated with inhibition of ovulation (injectable, implantable)
    • intrauterine device (IUD),
    • intrauterine hormone-releasing system (IUS),
    • bilateral tubal occlusion,
    • vasectomized partner,

    Birth control methods which may be considered as highly effective for men and that should last for 4 months after IMP administration include:

    • vasectomy,
    • use of condom combined with a highly effective birth control method for their WOCB partner.

    Please note that hormonal contraception is a risk factor for thromboembolic events and attention should be called to reconsider it passed the acute stroke phase.

  8. Women of child-bearing potential must have negative results of a plasma pregnancy test (serum betaHCG).
  9. Affiliation to social security or any health insurance

Exclusion Criteria:

  1. Contraindications to EVT;
  2. Contraindication to contrast agents
  3. Pre-existing neurologic and psychiatric disease with mRS ≥ 3;
  4. Unknown symptom's onset;
  5. Patients under or needing immediate DAPT administration;
  6. Patients previously treated by tenecteplase within 24 hrs;
  7. Significant mass effect with midline shift as confirmed on CT/MRI;
  8. Gastrointestinal or urinary tract hemorrhage in previous 21 days;
  9. Patient with intracranial haemorrhage
  10. Platelet count <100 000 mm3;
  11. Pregnant or breastfeeding woman;
  12. Known hypersensitivity to glenzocimab or to any of the excipients;
  13. Severe renal insufficiency (Grades 4-5) with a glomerular filtration rate < 30mL/Min/1.73m2;
  14. Participation in another interventional clinical trial within 30 days prior to the inclusion.
  15. Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under sections L.3212-1 et L.3213-1 and persons admitted to a health or social institution for purposes other than research (L.1121-6)
  16. Adults subject to a legal protection measure (L.1121-8)
  17. The patient or his/her family (if the patient is unable to give his/her opinion) expresses an inability to return for protocol visits
  18. patients receiving anticoagulants, as already mentioned in the non-authorized concomitant treatments
  19. patients who have already received another humanized fragment of monoclonal antibody with a suspicion of hypersensitivity

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Experimental

    Arm Label

    Placebo

    Glenzocimab

    Arm Description

    Outcomes

    Primary Outcome Measures

    Efficacy mRS 90
    The primary efficacy endpoint is the functional outcome assessed by the modified Rankin Scale (mRS) at day 90 +/- 15 days. The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. - No significant disability. Able to carry out all usual activities, despite some symptoms. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. - Moderate disability. Requires some help, but able to walk unassisted. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. - Dead.

    Secondary Outcome Measures

    Favorable functional outcome
    Favorable functional outcome defined by a mRS ≤ 2 at day 90 +/- 15 days
    Severe handicap
    Proportion of patients with a severe handicap: mRS equal to 4, 5 or 6 at day 90 +/- 15 days
    Survival
    Overall survival at 90 days and 1 year
    Early reperfusion outcomes : volume
    Stroke volume by MRI at 24 hrs
    Early reperfusion outcomes : eTICI
    Reperfusion at the end of procedure assessed by the expanded treatment in cerebral infarction (eTICI) score.The eTICI is defined as follows : grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)
    Early reperfusion outcomes NIHSS
    Early neurological improvement by National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) at 24 hrs. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
    Quality of life
    EQ5D-5L at day 90 and at 1 year. EQ-5D is a standardised measure of health-related quality of life. The EQ-5D-5L descriptive system uses five dimensions. The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems', and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). EQ-5D-5L is the sum of the five dimensions.
    IntraCranial Hemorrhages
    Incidence of symptomatic or non-symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Symptomatic IntraCranial Hemorrhages
    Incidence of symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Non-Symptomatic IntraCranial Hemorrhages
    Incidence of non-symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Adverse event
    Incidence, nature and severity of Adverse Events, SAEs, SUSARs, Bleeding-Related Events (BREs) and/or Treatment-Emergent Adverse Events (TEAEs), at 24 hrs, at D7/discharge, 30 days and 90 days
    Bleeding relating events
    Incidence of bleeding-related events at 90 days
    Anti-glenzocimab antibodies
    Anti-glenzocimab antibodies (ADA) blood concentration at 3 months for 50 patients.

    Full Information

    First Posted
    September 26, 2022
    Last Updated
    September 26, 2022
    Sponsor
    Assistance Publique - Hôpitaux de Paris
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05559398
    Brief Title
    Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
    Acronym
    GREEN
    Official Title
    Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 10, 2022 (Anticipated)
    Primary Completion Date
    October 10, 2025 (Anticipated)
    Study Completion Date
    October 10, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Assistance Publique - Hôpitaux de Paris

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patients remain disabled at 3 months. Reperfusion rates after MT are critical to determine functional outcome. However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Stroke, Acute, Stroke, Ischemic
    Keywords
    Platelet glycoprotein VI, Endovascular therapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    Randomized, double blinded, multicentre, placebo controlled study
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    260 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Title
    Glenzocimab
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Glenzocimab
    Intervention Description
    Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0. It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL. Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g. Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
    Primary Outcome Measure Information:
    Title
    Efficacy mRS 90
    Description
    The primary efficacy endpoint is the functional outcome assessed by the modified Rankin Scale (mRS) at day 90 +/- 15 days. The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. - No significant disability. Able to carry out all usual activities, despite some symptoms. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. - Moderate disability. Requires some help, but able to walk unassisted. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. - Dead.
    Time Frame
    90 days
    Secondary Outcome Measure Information:
    Title
    Favorable functional outcome
    Description
    Favorable functional outcome defined by a mRS ≤ 2 at day 90 +/- 15 days
    Time Frame
    90 days
    Title
    Severe handicap
    Description
    Proportion of patients with a severe handicap: mRS equal to 4, 5 or 6 at day 90 +/- 15 days
    Time Frame
    90 days
    Title
    Survival
    Description
    Overall survival at 90 days and 1 year
    Time Frame
    90 days and 1 year
    Title
    Early reperfusion outcomes : volume
    Description
    Stroke volume by MRI at 24 hrs
    Time Frame
    24 hours
    Title
    Early reperfusion outcomes : eTICI
    Description
    Reperfusion at the end of procedure assessed by the expanded treatment in cerebral infarction (eTICI) score.The eTICI is defined as follows : grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)
    Time Frame
    24 hours
    Title
    Early reperfusion outcomes NIHSS
    Description
    Early neurological improvement by National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) at 24 hrs. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
    Time Frame
    24 hours
    Title
    Quality of life
    Description
    EQ5D-5L at day 90 and at 1 year. EQ-5D is a standardised measure of health-related quality of life. The EQ-5D-5L descriptive system uses five dimensions. The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems', and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). EQ-5D-5L is the sum of the five dimensions.
    Time Frame
    90 days and 1 year
    Title
    IntraCranial Hemorrhages
    Description
    Incidence of symptomatic or non-symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Time Frame
    24 hours
    Title
    Symptomatic IntraCranial Hemorrhages
    Description
    Incidence of symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Time Frame
    24 hours
    Title
    Non-Symptomatic IntraCranial Hemorrhages
    Description
    Incidence of non-symptomatic IntraCranial Hemorrhages (ICH) at 24 hrs
    Time Frame
    24 hours
    Title
    Adverse event
    Description
    Incidence, nature and severity of Adverse Events, SAEs, SUSARs, Bleeding-Related Events (BREs) and/or Treatment-Emergent Adverse Events (TEAEs), at 24 hrs, at D7/discharge, 30 days and 90 days
    Time Frame
    24 hours, 7 days, 30 days, 90 days
    Title
    Bleeding relating events
    Description
    Incidence of bleeding-related events at 90 days
    Time Frame
    90 days
    Title
    Anti-glenzocimab antibodies
    Description
    Anti-glenzocimab antibodies (ADA) blood concentration at 3 months for 50 patients.
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 18 years or older (Age≥18 years) No significant pre-stroke disability (pre-stroke mRS must be equal to 0 or 1); Indication of EVT within the time-window of 0 to 24 hrs in participants treated with or without intravenous thrombolysis; Participants presenting with a target mismatch defined by an initial infarct volume (ischemic core) of less than 70 ml, a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more, and an absolute volume of potentially reversible ischemia (penumbra) of 15 ml or more on magnetic resonance imaging (MRI) or, when this is not possible, on perfusion computed tomography (CTP); Occlusion of the cervical or intracranial internal carotid artery (ICA) or the proximal middle cerebral artery (MCA - M1 and M2), on magnetic resonance angiography (MRA) or, when this is not possible, on CT angiography (CTA); Informed consent signed: By the patient Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent by written as per L. 1111-6, In a situation urgently and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow him to consent. Post-menopausal women defined as not having menses for 12 months without an alternative medical cause. For WOCBP, a highly effective birth control method should be in place that can achieve a failure rate of less than 1% per year that should last for at least 2 months after IMP administration. Birth control methods which may be considered as highly effective in WOCBP include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (injectable, implantable) intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, Birth control methods which may be considered as highly effective for men and that should last for 4 months after IMP administration include: vasectomy, use of condom combined with a highly effective birth control method for their WOCB partner. Please note that hormonal contraception is a risk factor for thromboembolic events and attention should be called to reconsider it passed the acute stroke phase. Women of child-bearing potential must have negative results of a plasma pregnancy test (serum betaHCG). Affiliation to social security or any health insurance Exclusion Criteria: Contraindications to EVT; Contraindication to contrast agents Pre-existing neurologic and psychiatric disease with mRS ≥ 3; Unknown symptom's onset; Patients under or needing immediate DAPT administration; Patients previously treated by tenecteplase within 24 hrs; Significant mass effect with midline shift as confirmed on CT/MRI; Gastrointestinal or urinary tract hemorrhage in previous 21 days; Patient with intracranial haemorrhage Platelet count <100 000 mm3; Pregnant or breastfeeding woman; Known hypersensitivity to glenzocimab or to any of the excipients; Severe renal insufficiency (Grades 4-5) with a glomerular filtration rate < 30mL/Min/1.73m2; Participation in another interventional clinical trial within 30 days prior to the inclusion. Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under sections L.3212-1 et L.3213-1 and persons admitted to a health or social institution for purposes other than research (L.1121-6) Adults subject to a legal protection measure (L.1121-8) The patient or his/her family (if the patient is unable to give his/her opinion) expresses an inability to return for protocol visits patients receiving anticoagulants, as already mentioned in the non-authorized concomitant treatments patients who have already received another humanized fragment of monoclonal antibody with a suspicion of hypersensitivity
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    mikael Mazighi, MD PHD
    Phone
    1 49 95 25 97
    Ext
    +33
    Email
    mikael.mazighi@aphp.fr
    First Name & Middle Initial & Last Name or Official Title & Degree
    matthieu resche-rigon, MDPHD
    Phone
    142499742
    Ext
    +33
    Email
    matthieu.resche-rigon@u-paris.fr

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

    We'll reach out to this number within 24 hrs